Announcement

Collapse
No announcement yet.

Nat Med . Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Nat Med . Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization


    Nat Med


    . 2023 Mar 23.
    doi: 10.1038/s41591-023-02270-2. Online ahead of print.
    Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization


    Michal Lipschuetz # 1 2 , Joshua Guedalia # 1 , Sarah M Cohen 1 , Yishai Sompolinsky 1 , Galit Shefer 3 , Eli Melul 3 , Zivanit Ergaz-Shaltiel 4 , Debra Goldman-Wohl 1 , Simcha Yagel 1 , Ronit Calderon-Margalit 5 , Ofer Beharier 6



    Affiliations

    Abstract

    Infants are at a higher risk of Coronavirus Disease 2019 (COVID-19)-related hospitalizations compared to older children. In this study, we investigated the effect of the recommended third maternal dose of BNT162b2 COVID-19 vaccine during pregnancy on rates of infant COVID-19-related hospitalizations. We conducted a nationwide cohort study of all live-born infants delivered in Israel between 24 August 2021 and 15 March 2022 to estimate the effectiveness of the third booster dose versus the second dose against infant COVID-19-related hospitalizations. Data were analyzed for the overall study period, and the Delta and Omicron periods were analyzed separately. Cox proportional hazard regression models estimated hazard ratios and 95% confidence intervals (CIs) for infant hospitalizations according to maternal vaccination status at delivery. Among 48,868 live-born infants included in the analysis, rates of COVID-19 hospitalization were 0.4%, 0.6% and 0.7% in the third-dose, second-dose and unvaccinated groups, respectively. Compared to the second dose, the third dose was associated with reduced infant hospitalization with estimated effectiveness of 53% (95% CI: 36-65%). Greater protection was associated with a shorter interval between vaccination and delivery. A third maternal dose during pregnancy reduced the risk of infant hospitalization for COVID-19 during the first 4 months of life, supporting clinical and public health guidance for maternal booster vaccination to prevent infant COVID-19 hospitalization.


Working...
X